Autologous bone marrow transplantation multiple myeloma identification prognostic factors Multiple myeloma fatal malignancy median survival time years clinical trial feasibility efficacy marrow-ablative chemoradiotherapy unpurged autologous bone marrow ABMT prognostic variables Total body irradiation melphalan thiotepa patients median age years years group patients resistance melphalan-prednisone continuous infusions vincristine Adriamycin high dose dexamethasone VAD primary unresponsive disease resistant relapse patients remission VAD regimen first subsequent remission cytoreduction equal patients refractory myeloma cytoreduction magnitude patients remission VAD early deaths patients patients resistant relapse none complete remission group median durations relapse-free overall survival months patients early death complete remission incidence patients first remission survival rate regardless disease status remission primary resistance information sensitivity therapy unavailable presence ABMT high levels mg/L non-IgG isotype patients poor prognosis responders months patients months contrast projected survival rate patients series investigation novel treatment approach comparison standard dose regimens results marrow-ablative therapy myeloma patients resistant relapse combination risk factors advanced tumor burden absence IgG isotype apparent lack adverse effect plasmacytosis autografts need cytoreduction marrow purging 